Aktiesnakken — August 2010
-
læs den her... http://www.aseanbiotechnology.info/Abstract/21019932.pdf
-
der står bl.a. - or working with an existing
laboratory that is compliant with the Clinical
Laboratory Improvement Amendments of
1988 (CLIA -
to market their diagnostic as
a so-called ‘homebrew.’
Yet another route is to sell one or more of
the components of their diagnostic to tes -
to testing
laboratories as analyte-specific reagents
(ASRs), thus enabling early market penetration
and enhancing early adoption of their
t -
their
technology. -
det betyder... hold fast, at BioPorto i realiteten, kunne kjøbe et laboratorie i USA, lave en home brew godkendelse, og vupti.. sælge deres
-
homogene test i USA
-
eller, de kunne brække den op i 2 elementer, og sælge den under analyte-specific reagents
(ASRs) -
usa stiger, nu kun lille minus
-
det er det sikkert
-
så mange aktier har bioporto ikke
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind